Health Information About Soft Tissue Sarcoma
Soft-tissue sarcoma: Information from Answers.com
|
 | Key Terms: Alveolar rhabdomyosarcoma, Brachytherapy, Cytogenetics, Dermatofibrosarcoma protuberans, Embryonal rhabdomyosarcoma, Epithelioid hemangioendothelioma ... more... | Soft-tissue sarcoma - Wikipedia, the free encyclopedia
|
 | A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is sometimes applied to elements of the soft tissue that are not ... more... | Soft Tissue Sarcomas - National Cancer Institute
|
 | A fact sheet about soft tissue sarcomas, cancers that develop in tissues that connect, support, or surround other structures and organs of the body. National Cancer ... more... | Sarcoma Facts | Sarcoma | Seattle Cancer Care Alliance
|
 | The majority of the cases (close to 8,000) are soft tissue sarcomas; the other 2,000 or so are bone cancers. Patients with a soft tissue sarcoma typically present with a ... more... | Soft Tissue Sarcoma: MedlinePlus
|
 | Your soft tissues connect, support or surround other tissues. Examples include your muscles, tendons, fat and blood vessels. Soft tissue sarcoma is a cancer of these ... more... |
Soft Tissue Sarcoma News
soft tissue sarcoma - Bing News
IMPORTANT: Bing News RSS feed has moved!
|
read more...
|
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
|
Threshold to receive $25 million upfront, plus further potential milestones and royalties Deal provides Threshold option to co-commercialize in the United States Phase 3 trial in
read more...
|
Merck KGaA and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
|
TH-302 is currently being investigated in a global Phase III clinical trial in patients with
read more...
|
Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M
|
The small molecule hypoxia-targeted drug is currently undergoing a Phase III trial as combination therapy with doxorubicin in patients with
read more...
|
Threshold Pharmaceuticals to co-develop and market TH-302 with Merck
|
TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with
read more...
|
|
|
|
